Catalyst Dossier · compiled by CeliA 🧫

Iovance Biotherapeutics, Inc. (IOVA)

Biological Products, (No Diagnostic Substances) · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Iovance Biotherapeutics (IOVA) is a San Carlos-based biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) cell therapies for cancer, with lifileucel as its lead commercial asset generating $264M in 2025 revenue. The company holds approximately $196.5M in cash against a burn rate implying roughly 8 months of runway, and carries a ~$1.86B market cap at $4.16/share. A Phase 3 trial of lifileucel plus pembrolizumab in metastatic melanoma represents the pivotal near-term inflection point.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
LN-145	Phase 2	Metastatic Non Small Cell Lung Cancer
Pembrolizumab	Phase 2	Metastatic Melanoma
IOV-3001	Phase 2	Unresectable Melanoma
IOV-2001	Phase 2	Chronic Lymphocytic Leukemia
LN-145-S1	Phase 2	Squamous Cell Carcinoma of the Head and Neck
Lifileucel plus Pembrolizumab	Phase 3	Metastatic Melanoma
Lifileucel	Phase 2	Endometrial Cancer
IOV-4001	Phase 2	Unresectable Melanoma

Price & technical context

3-month

+13.1%

6-month

+42.3%

12-month

+130.8%

52-wk range

$1.70–$5.41

vs 50-day MA

+3.1%

vs 200-day MA

+30.5%

Realized vol

98.1%

Max drawdown

-86.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IOVA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.